Sophia Genetics SA

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 shares of common stock on October 12, 2026 for $7.26 per share.

Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 4,000 shares of common stock on October 13, 2026 for $7.18 per share.

Jurgi Camblong, Executive Chairman and a Director of SOPHiA GENETICS SA, sold 8,500 shares of common stock on October 12, 2026 for $7.26 per share.

Well Daan Van, Chief Legal Officer of SOPHiA GENETICS SA, sold 6,168 shares of common stock on October 5, 2026 for $8.12 per share.

Manuela Valente, Chief People Officer of SOPHiA GENETICS SA, sold 4,240 shares of common stock on October 5, 2026 for $8.13 per share.

Abhimanyu Verma, Chief Technology Officer of SOPHiA GENETICS SA, sold 5,284 shares of common stock on October 5, 2026 for $8.12 per share.

Balderton Capital VI, S.L.P. has filed an Amendment No. 3 to its Schedule 13G, reporting beneficial ownership of 4.9% of Sophia Genetics SA's Ordinary Shares.

Akre Capital Management, LLC, along with Braddock Partners Offshore, LP and Braddock Capital Offshore, LLC, has disclosed a passive beneficial ownership of 5.6% in SOPHiA GENETICS SA, totaling 3,719,140 ordinary shares.